Show simple item record

dc.contributor.authorHAMPEL, HARALD
dc.date.accessioned2009-10-28T15:39:16Z
dc.date.available2009-10-28T15:39:16Z
dc.date.issued2009
dc.date.submitted2009en
dc.identifier.citationHarald Hampel, Kaj Blennow, Leslie M. Shaw, Yvonne C. Hoessler, Henrik Zetterberg and John Q. Trojanowski `Total and phosphorylated Tau protein as biological markers of Alzheimer?s disease? in Experimental Gerontology, 2009en
dc.identifier.otherY
dc.identifier.other62001
dc.identifier.otherYen
dc.identifier.urihttp://hdl.handle.net/2262/34386
dc.descriptionIN_PRESSen
dc.description.abstractAdvances in our understanding of tau-mediated neurodegeneration in Alzheimer?s disease (AD) are moving this disease pathway to center stage for the development of biomarkers and disease modifying drug discovery efforts. Immunoassays were developed detecting total (t-tau) and tau phosphorylated at specific epitopes (p-tauX) in cerebrospinal fluid (CSF), methods to analyse tau in blood are at the experimental beginning. Clinical research consistently demonstrated CSF t- and p-tau increased in AD compared to controls. Measuring these tau species proved informative for classifying AD from relevant differential diagnoses. Tau phosphorylated at threonine 231 (p-tau231) differentiated between AD and frontotemporal dementia, tau phosphorylated at serine 181 (p-tau181) enhanced classification between AD and dementia with Lewy bodies. T- and p-tau are considered ?core? AD biomarkers that have been successfully validated by controlled large-scale multi-center studies. Tau biomarkers are implemented in clinical trials to reflect biological activity, mechanisms of action of compounds, support enrichment of target populations, provide endpoints for proof-of-concept and confirmatory trials on disease modification. World-wide quality control initiatives are underway to set required methodological and protocol standards. Discussions with regulatory authorities gain momentum defining the role of tau biomarkers for trial designs and how they may be further qualified for surrogate marker status.en
dc.description.sponsorshipThis work was supported by a Science Foundation Ireland (SFI) investigator program award 08/IN.1/B1846 to HH, by grants from the NIH (AG-10124 and AG- 24904) to JQT and LMS, and by grants from the Swedish Research Council (2006-6227 and 2006-2740) to HZ and KB, Alzheimer?s Association (NIRG-08-90356) to HZ and KB, and the Royal Swedish Academy of Sciences (FOTKAW09-039-A) to HZen
dc.format.extent952027 bytes
dc.format.mimetypeapplication/pdf
dc.language.isoenen
dc.publisherElsevieren
dc.relation.ispartofseriesExperimental Gerontologyen
dc.rightsYen
dc.subjectAlzheimer?s disease; MCI; neurodegeneration; biomarker; prediction; diagnosis; blood; CSF; tau; p-tauen
dc.titleTotal and phosphorylated Tau protein as biological markers of Alzheimer's diseaseen
dc.typeJournal Articleen
dc.contributor.sponsorScience Foundation Ireland
dc.contributor.sponsorSwedish Research Council
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/hampel
dc.identifier.rssurihttp://dx.doi.org/10.1016/j.exger.2009.10.010


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record